Iulie 2022: Potrivit celei mai recente cercetări efectuate de Emergen Research, piața globală pentru terapia cu celule T CAR a atins o dimensiune de 1.29 miliarde USD în 2021 și este de așteptat să înregistreze un CAGR de 24.9% pe parcursul perioadei de prognoză. Incidența în creștere a cancerului în întreaga lume, precum și rata în creștere a mortalității cauzate de cancer sunt de așteptat să fie principalii factori de creștere a veniturilor pe piața globală a terapiei cu celule CAR-T pe parcursul perioadei de prognoză. Extinderea activităților de studii clinice într-un ritm vertiginos, proliferarea fuziunilor și achizițiilor și atractivitatea ofertelor publice inițiale sunt toți factori care contribuie la creșterea veniturilor pe piața globală a terapiei cu celule T CAR.
The primary objective of the report is to provide an overview of the market, including product scope, growth prospects, and potential risks. In-depth information about each participant in the global Terapia cu celule T CAR market, including that participant’s global standing, financial status, product launch, and business expansion plans, is included in the report. The participants in the market are concentrating their efforts on the creation of a variety of strategies, including partnerships, mergers and acquisitions, joint ventures, product launches, and investments in research and development.
According to the findings of the study, there are certain types of dangers and difficulties that can serve as an obstacle for a company. Granularity can be added to the overall research by performing an in-depth analysis of the Terapia cu celule T CAR market in the context of various aspects of the larger environment, such as the social, political, economic, and technological settings. In addition, the study generates real-time data on essential aspects such as sales, profits, gross margin, and growth prospects to demonstrate how going forward the company will see a significant upswing in its performance.
Alte constatări semnificative din raport indică faptul că
In 2021, the segment of diffuse large B-cell limfom was responsible for the majority of the rapid revenue share. A cancer of the lymphatic system, which is an essential component of the immune system, called diffuse large B-cell lymphoma has a rapid growth rate. It has an effect on the blood cells that generate antibodies, which are used to fight infections. In certain instances, DLBCL can be cured. The majority of patients suffering from DLBCL have a favourable response to initial treatments such as chemotherapy. In the case of some people, the illness either becomes resistant to treatment, which means that it no longer responds to it, or it relapses, which means that it returns after treatment has been completed. These patients may be candidates for treatment with terapia cu celule T cu receptorul antigen himeric, which utilises the patient’s own immune cells in the fight against DLBCL. T-cells are taken out of the patient’s blood, modified in the laboratory with so-called chimeric antigen receptors that help in recognising and destroying cancer cells, and then reintroduced into the patient’s blood again. This process is repeated several times.
In 2021, the hospital segment was responsible for a fair amount of the total revenue. The CAR T-cell therapy will reprogramme the patient’s T-cells so that they will target the antigens produced by the tumour. CAR T-cell therapy has shown full remission rates of 80 to 90 percent in younger patients with B-cell acute lymphoblastic leukaemia, and it has shown a full remission rate of 40 percent in patients with symptomatic B-cell limfoame non-Hodgkin who have failed several prior lines of therapy. Both of these patient populations have B-cell acute lymphoblastic leukaemia.
Companiile cheie care operează în prezent pe piață sunt investigate în continuare în acest raport, la fel ca și profilurile companiei, portofoliile de produse, strategiile de expansiune și alianțele strategice ale acestora. Câteva exemple de aceste tipuri de alianțe includ fuziuni și achiziții, colaborări și asociații în participațiune. În plus, oferă informații importante despre realizările și situația financiară ale companiei, precum și informații despre acoperirea pe piață și poziția globală a companiei.
Companii profilate pe piața globală CAR T-Cell Therapy:
Novartis AG, Pfizer Inc., CARsgen Therapeutics Co., Ltd., Daiichi Sankyo Company, Limited, Bristol-Myers Squibb Company, Astellas Pharma Inc., BioNTech SE, Biocad, F. Hoffmann-La Roche Ltd. și Eli Lilly and Company .
Citiți mai multe despre raportul global de piață CAR T-Cell Therapy la: https://www.emergenresearch.com/industry-report/car-t-cell-therapy-market
